BioVie (BIVI) Stock Price, News & Analysis

Company Overview

BioVie Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for neurological, neurodegenerative and inflammatory diseases. Its research programs are aimed at addressing disease mechanisms such as chronic inflammation, insulin resistance and impaired cellular signaling.

The company's lead investigational product, bezisterim (also known as NE3107), is an orally administered, blood-brain barrier-penetrating small molecule being studied for potential use in disorders including Alzheimer's disease and Parkinson's disease. BioVie has also developed BIV201, an investigational continuous-infusion formulation of terlipressin intended to treat refractory ascites associated with advanced liver cirrhosis.

BioVie conducts clinical development activities primarily in the United States and works with research institutions and clinical investigators to evaluate its product candidates. The company is headquartered in Carson City, Nevada, and is led by President and Chief Executive Officer Cuong Do.

Key Stats

• Today's Range: $1.40 to $2.66
• 50-Day Range: $1.13 to $2.28
• 52-Week Range: $0.82 to $3.79
• Volume: 13.31 million shs
• Average Volume: 173,852 shs
• Market Capitalization: $15.02 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

BioVie Stock Analysis - MarketRank™

BioVie scored higher than 27% of companies evaluated by MarketBeat, and ranked 772nd out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

BioVie has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

BioVie has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of BioVie is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BioVie is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

BioVie has a P/B Ratio of 1.27. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

7.53% of the float of BioVie has been sold short.

Short Interest Ratio / Days to Cover

BioVie has a short interest ratio ("days to cover") of 2.76, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BioVie has recently decreased by 34.51%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BioVie does not currently pay a dividend.

Dividend Growth

BioVie does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.43

News Sentiment

BioVie has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for BioVie this week, compared to 3 articles on an average week.

Search Interest

4 people have searched for BIVI on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

4 insiders have purchased shares of BioVie in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $49,118.00 in company stock, which represents 0.3271% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, BioVie insiders have bought more of their company's stock than they have sold. Specifically, they have bought $49,118.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

16.70% of the stock of BioVie is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

4.59% of the stock of BioVie is held by institutions.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 11/03/2026
• Next Earnings (Estimated): 11/09/2026
• AGM 2026: 11/10/2026
• Fiscal Year End: 6/30/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:BIVI
• CIK: 1580149
• Web: bioviepharma.com
• Phone: (775) 888-3162
• Fax: N/A
• Employees: 13
• Year Founded: 2013

Profitability

• EPS (Trailing Twelve Months): ($3.15)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$22.07 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -126.02%
• Return on Assets: -108.88%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.59
• Quick Ratio: 3.59

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.36 per share
• Price / Book: 1.27

Miscellaneous

• Outstanding Shares: 8,680,000
• Free Float: 7,233,000
• Market Cap: $15.02 million
• Optionable: No Data
• Beta: 0.78